Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen.

Reducing the synthesis of apoC-III reduces fasting triglycerides in individuals lacking lipoprotein lipase activity. Recently, Stroes et al. ¹ published a phase 3 trial on the effects of olezarsen, a third-generation antisense oligonucleotide that blocks apoC-III mRNA, on triglycerides and risk of acute pancreatitis.
Competing Interests: Declaration of interests P.V. received honoraria for presentations and advisory boards from AMGEN, Sanofi, Servier, Novartis, MSD, Alexion, Sobi, Akcea, and PTB. P.V. also received research grants from Ferrer and Sobi and technology transfer contracts with Lipigon Pharmaceuticals and Capenergy Medical.
(Copyright © 2024 Elsevier Inc. All rights reserved.)